Abstract Purpose Estrogen Receptor α (ERα) is a well-established therapeutic target for
Estrogen Receptor (ER)-positive breast cancers. Both Selective Estrogen Receptor …

Estrogen receptor α (ERα) is a prime target for the treatment of ER-positive (ER+) breast
cancer. Despite the development of several effective therapies targeting ERα signaling …

Background The oestrogen receptor (ER) is an important therapeutic target in ER-positive
(ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients …

Purpose Studies have identified several estrogen receptor α (ERα) ligand-binding domain
(LBD) somatic mutations in endocrine therapy resistant, metastatic ER-positive breast …

It has become apparent of late that even in tamoxifen and/or aromatase resistant breast
cancers, ERα remains a bona fide therapeutic target. Not surprisingly, therefore, there has …

Nearly 70% or more of newly diagnosed cases of breast cancer (BC) are estrogen receptor
positive (ER+) where endocrine therapy is a primary treatment. However, substantial …

Estrogen and the estrogen receptor (ER) are known to be prominent drivers of breast
tumourigenesis and breast cancer progression. Hormonal agents that target the ER such as …

Anti-hormonal therapy has been the mainstay treatment for estrogen receptor (ER)+ ve
breast cancer for> 40 years. The selective ER degrader (SERD) fulvestrant has …

The estrogen receptor alpha (ERα) is expressed in> 70% of breast cancers and is a
clinically validated target in oncology. Anti-hormonal therapies that block ER function directly …

Estrogen receptor positive (ER+) breast cancer accounts for 70% of all breast cancers and is
primarily treated with endocrine therapy. Approximately 40% of patients on endocrine …